September 11, 2023
Hamburg, Germany—September 11th, 2023 Indivumed Services GmbH, a Crown Bioscience company, announced that its Hamburg site received laboratory accreditation from the College of American Pathologists (CAP). The CAP accreditation, recognized as the gold standard for laboratory quality control in the industry, is reserved for top-tier laboratories that meet and maintain the highest standards of quality, accuracy, and consistency in the testing of clinical biospecimens. This distinction places Indivumed Services among the top 10% of laboratories globally, solidifying its commitment to excellence in laboratory services.
This achievement strengthens Indivumed Services’ global reputation in providing and analyzing clinical biospecimens, while paving the way for future Clinical Laboratory Improvement Amendments (CLIA) certification. This certification will enable the analysis of patient-derived samples across all clinical trial phases, ensuring expert end-to-end support from assay development utilizing Indivumed Services’ industry leading biobank, through to analyzing samples from downstream clinical research.
Overall, Indivumed Services’ CAP accreditation enhances its flexibility and enables the expansion of its services into new markets. This will foster stronger partnerships, ultimately benefiting both existing and new customers.
Simone Hubo, PhD, Vice President of Quality and Regulatory Affairs at Indivumed Services, stated: “With this accreditation, our customers can rest assured that the samples and analyses provided by Indivumed Services are of industry-leading quality. This means they can have confidence that the laboratory is performing at the highest global standard for quality.”
Armin Spura, PhD, Chief Executive Officer of Crown Bioscience, added: “When Crown Bioscience identified Indivumed Services as a potential acquisition, one of the key attributes that attracted us was the high quality of the operations teams and their ability to continue to support clients through the transition from preclinical to clinical development. Obtaining CAP accreditation validates this assessment and solidifies our commitment to advancing our translational research platforms so that we can provide superior options for bridging the gap between preclinical and clinical research. This achievement is a testament to the expertise of our highly qualified professionals and the cutting-edge technologies they expertly use.”
Media Inquiries:
Crown Bioscience
Sarah Martin-Tyrrell
pr@crownbio.com
